APRICUS BIO CEO BASSAM DAMAJ TO PRESENT AT THE 2011 BIOTECHNOLOGY INDUSTRY ORGANIZATION (BIO) INTERNATIONAL CONVENTION
Company to Discuss New Analysis of the US Phase III trials of MycoVa™ and Development of the Room Temperature Version of Vitaros®
SAN DIEGO, June 24, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) (http://www.apricusbio.com) Chairman, President and Chief Executive Officer, Dr. Bassam Damaj, will present at the BIO International Conference in Washington, D.C. Dr. Damaj will deliver his presentation on Tuesday, June 28, 2011 at 10:15 a.m. at the Walter E. Washington Convention Center in Washington, D.C. In addition to a corporate presentation, Dr. Damaj will discuss the room temperature version of Vitaros® for erectile dysfunction, which is expected to have a shelf life of two years; Dr. Damaj will also present the latest positive analysis done by the key opinion leader, Dr. A. Gupta, at Mediprobe Research, of the US Phase III trials of the Company's anti-fungal drug candidate MycoVa™.
The BIO International Convention is the largest global event for the biotechnology industry.
Vitaros® and MycoVa™ utilize Apricus Bio's proprietary NexACT® drug delivery technology, which enables the rapid absorption of various active pharmaceutical ingredients through the skin, with the goal of improving patient outcomes and reducing side effects.
Dr. Damaj's presentation at the BIO International Conference will be accessible to the public on the Apricus Bio web site at http://www.apricusbio.com.
Vitaros® is approved for sale in Canada and is expected to be on the market in that country during the second half of 2011. Apricus Bio has filed a marketing application filing for Vitaros® in Europe, and the Company expects to file a marketing application in Switzerland.
The Company is seeking guidance from the regulatory agencies to file for market authorization of MycoVa™ in Europe, Canada and the US. It is also seeking guidance from regulatory agencies for Femprox® , its product for the treatment of female sexual arousal disorder in Europe and Canada.
For additional background on the Company's NexACT® drug delivery technology, Apricus Bio has produced and posted on its website a series of videos at http://www.apricusbio.com/video_faq.html
Other later stage drugs in Apricus Bio's pipeline include: PrevOnco™, a treatment for hepatocellular liver carcinoma and RayVa™, for Raynaud's Syndrome.
About Apricus Biosciences, Inc.
Apricus Bio, a San Diego based revenue-generating specialty biopharmaceutical company, has leveraged the flexibility of its clinically-validated NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes.
Revenues and growth are driven from out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies worldwide. In addition, the Company is seeking to monetize its existing product pipeline, including its first product, Vitaros® , approved in Canada for the treatment of erectile dysfunction, which is currently expected to be available on the Canadian market in 2011, as well as compounds in development from pre-clinical through Phase III, currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Cosmeceuticals among others.
For further information on Apricus Bio, visit http://www.apricusbio.com, and for information on its subsidiaries please visit http://www.nexmedusa.com or http://www.bio-quant.com. You can also receive information at http://twitter.com/apricusbio and http://facebook.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its ability to develop the room temperature version of Vitaros® for erectile dysfunction and the development of MycoVa™ for nail fungus, further development of its other products and product candidates, have such products and product candidates approved by relevant regulatory authorities in a timely fashion, to successfully commercialize and launch the room temperature version of Vitaros® , MycoVa™ and Femprox® and such other products and product candidates and to achieve its other development, commercialization and financial goals such as its revenue projections from the sale of its products. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
Apricus Biosciences, Inc.
Edward Cox, V.P.
Investor Relations & Corporate Development Apricus Bio, Inc.
Apricus Bio Investor Relations
Apricus Bio, Inc. Rx Communications Group, LLC